EUVIMEDEUVIMED entdecken
Crossref

Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?

Juliana CN. Chan, Chow Elaine, Alice Kong, Elaine Cheung, Tony O, Cadmon Lim, Baoqi Fan, Sandra Tsoi, Yingnan Fan, Mai Shi, Risa Ozaki, Ronald Ma und 1 weitere

Journal of Translational Genetics and Genomics · 19.01.2024 · 8 (1) · 13-34

DOI: 10.20517/jtgg.2023.36 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Translational Genetics and Genomics, online erschienen am 19.01.2024. Verfasst von Juliana CN. Chan und 12 weiteren Autor:innen. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 157 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Young-onset type 2 diabetes (YOD), defined as diabetes diagnosis before age 40, has an aggressive clinical course with premature mortality, in part due to long disease duration and lack of evidence to guide diagnosis and management. Autoimmune type 1 diabetes, maturity-onset diabetes of the young (MODY), and latent autoimmune diabetes in adults (LADA) are subtypes of diabetes in young people, which, however, cannot fully explain their complex clinical course. Similarly, family members carrying the same rare genetic variant of monogenic diabetes can have different presentations and outcomes. Ancestral heterogeneity, ecological transition, inter-ethnic differences in genomic architecture, and variations in living environment, lifestyles, access to care, and timeliness of diagnosis and treatment can influence the age of diagnosis and exposure to these cardiometabolic-renal risk factors. Despite the wealth of literature on genetic associations with diabetes, the familial cosegregation of rare variants and their relevance to YOD remains uncertain. This perspective was motivated by decades of clinical observations and learnings from an ongoing randomized controlled trial that uses biogenetic markers to classify patients with YOD for improving outcomes. Apart from highlighting the need to use family-based studies to improve the precision of diagnosis, we discussed atypical causes for diabetic ketoacidosis and the importance of lifecourse and psychosocial-behavioral factors in patients with YOD. Apart from detailed clinical evaluation, we propose using plasma C peptide, homeostasis model of assessment (HOMA) indexes, autoantibodies, and polygenic risk scores to stratify risk, classify diabetes subtypes, and personalize treatment in YOD. To achieve these goals, we advocate changing the practice environment and team structure to enable physicians to use the insights they learn from patients and their family members to implement precision medicine and improve the outlook of these high-risk individuals.

Zitieren

APA

Chan, J. C., Elaine, C., Kong, A., Cheung, E., O, T., Lim, C., Fan, B., Tsoi, S., Fan, Y., Shi, M., Ozaki, R., Ma, R., & Luk, A. (2024). Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?. Journal of Translational Genetics and Genomics, 8(1), 13-34. https://doi.org/10.20517/jtgg.2023.36

Vancouver

Chan JC, Elaine C, Kong A, Cheung E, O T, Lim C, et al. Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?. Journal of Translational Genetics and Genomics. 2024;8(1):13-34. doi:10.20517/jtgg.2023.36

BibTeX
@article{Chan2024,
  author = {Chan, Juliana CN. and Elaine, Chow and Kong, Alice and Cheung, Elaine and O, Tony and Lim, Cadmon and Fan, Baoqi and Tsoi, Sandra and Fan, Yingnan and Shi, Mai and Ozaki, Risa and Ma, Ronald and Luk, Andrea},
  title = {Multifaceted nature of young-onset diabetes - can genomic medicine improve the precision of diagnosis and management?},
  journal = {Journal of Translational Genetics and Genomics},
  year = {2024},
  volume = {8},
  number = {1},
  pages = {13--34},
  doi = {10.20517/jtgg.2023.36}
}
Kostenlos starten →